CJC-1295 + Ipamorelin 5mg+5mg

Format: Lyophilized fixed-ratio research blend in a sealed vial
Vial content: 5mg CJC-1295 without DAC + 5mg Ipamorelin (10mg combined)
Quantity options: 1, 2, 5 or 10 vials
Use classification: Laboratory research only
Packaging note: Cap colour may vary by batch

This fixed-ratio blend combines CJC-1295 without DAC, a growth-hormone-releasing hormone analogue, with Ipamorelin, a growth-hormone secretagogue receptor agonist. It is catalogued for controlled laboratory studies of GH-axis signalling and interactions between the two compounds. See the product resources below for related research context and sources.

This vial contains 10 mg total active material: 5 mg CJC-1295 and 5 mg Ipamorelin. Add 2 mL of bacteriostatic water to create a solution containing 2.5 mg/mL of each peptide, or 5 mg/mL combined. On a U-100 syringe, 10 units equals 0.1 mL, which contains 0.25 mg of each peptide, or 0.5 mg combined.

Store lyophilized vials in a cool, dry, dark location until ready for laboratory use. Keep vials sealed and protected from moisture, direct light, and unnecessary temperature fluctuation. After reconstitution, store refrigerated unless your validated protocol specifies otherwise. Minimize repeated warming and cooling, avoid repeated freeze-thaw cycles, and label prepared vials with the preparation date and concentration.

Orders ship from Canadian inventory to eligible Canadian addresses. Tracking is provided after dispatch; transit time varies by route and carrier.

Supplier-provided reports are published for selected products and strengths in the Certificates library. Each report identifies the tested sample strength and measured results.

How to read an analytical report

Tested sample: 5mg + 5mg.

View certificate